Sort
21,453 grants matching “tuberculosis”
Characterization of activity and mechanism of novel fungicidal anti-cryptococcal molecules
$230,250Damian J Krysan · University Of Rochester · R21 · FY2016 · AI
DAART+ AS A STRUCTURAL HIV INTERVENTION IN METHADONE MAINTENANCE
$230,250James L. Sorensen · University Of California, San Francisco · R21 · FY2006 · DA
A Novel Model of, and Pre-clinical Therapy for, Scleroderma Lung Disease
$230,250Sergei P Atamas · University Of Maryland Baltimore · R21 · FY2011 · HL
Novel inhibitors of 1-deoxy-D-xylulose-5-phosphate reductoisomerase (DXR)
$230,250Yongcheng Song · Baylor College Of Medicine · R21 · FY2010 · AI
Identification of Protein-Protein Interactions and Processing Events That Traffic and Activate the Bactericidal Pore-Forming Protein Perforin-2
$230,250George Patrick Munson · University Of Miami School Of Medicine · R21 · FY2022 · AI
Immunotherapeutic Potential of Modified Lipooligosaccharides and Lipid A's
$230,225Robert K Ernst · University Of Maryland Baltimore · R21 · FY2014 · AI
Cell envelope integrity in mycobacteria: interplay of lipoglycans, peptidoglycan, and capsular polysaccharides
$230,220Yasu S Morita · University Of Massachusetts Amherst · R21 · FY2023 · AI
GLYCOPROTEINS OF MYCOBACTERIUM TUBERCULOSIS
$230,201Colorado State University-Fort Collins · R01 · FY2002 · AI
The effect of type I IFN and IL-12 signaling on T cell immunity to tuberculosis
$230,199Samuel M Behar · Brigham And Women'S Hospital · R21 · FY2012 · AI
Role of IFNs and IFNGR in susceptibility to bacteria in Down syndrome
$230,121Laurel L Lenz · University Of Colorado Denver · R21 · FY2021 · AI
Modified DNA Aptamers and DNAzymes for Diagnosing TB in Resource-Poor Settings
$230,119Dan L. Feldheim · University Of Colorado · R21 · FY2012 · AI
Menaquinone Biosynthesis in M. Tuberculosis
$230,063State University New York Stony Brook · R21 · FY2005 · AI
Targeted Antimicrobial Treatment of Acne Vulgaris with a novel class of Enzybiotics from Mycobacteriophage lysterases
$229,997James K. Wang · Dermalytica, Inc. · R43 · FY2016 · AR
Using systems science to optimize the impact of point-of-care viral load testing for pediatric HIV management
$229,941Rena Chiman Patel · University Of Washington · R21 · FY2020 · MH
Engagement with healthcare system, tobacco use and cancer communication during COVID-19 in India - Administrative Supplement to Project LifeFirst SWASTH
$229,903Kasisomayajula Viswanath · Dana-Farber Cancer Inst · R01 · FY2021 · CA
Core--International Studies
$229,882Harvey A. Friedman · University Of Pennsylvania · P30 · FY2008 · AI
A "radical" approach to tuberculosis infection
$229,839Deborah T Hung · Broad Institute, Inc. · R21 · FY2014 · AI
Vitamin D supplementations as adjunct to anti-tuberculosis drugs in Mongolia
$229,765Ganmaa Davaasambuu · Harvard School Of Public Health · R00 · FY2011 · HL
Investigating the Role of Protease-mediated signaling in M. tuberculosis Virulence
$229,727Bennett Penn · University Of California At Davis · R21 · FY2022 · AI
Training CHWs to Support Re-Engagement in TB/HIV Care in the Context of Depression and Substance Use
$229,713Jessica F Magidson · Univ Of Maryland, College Park · R34 · FY2021 · MH
Overcoming Pyrazinamide Resistance with Pyrazinoate-Cephalosporin Conjugates
$229,632Courtney C Aldrich · University Of Minnesota · R21 · FY2020 · AI
The in vivo effect of vitamin D on Mycobacterium tuberculosis infection
$229,628Padmini Salgame · Rbhs-New Jersey Medical School · R21 · FY2016 · AI
CD1-RESTRICTED T CELLS AGAINST THE TULAREMIA PATHOGEN
$229,626University Of California Los Angeles · R21 · FY2004 · AI
New Hampshire Tuberculosis Elimination & Laboratory Program
$229,621Jose Their Montero · Nh State Dept/Hlth Statistics/Data Mgmt · U52 · FY2012 · PS
INTERNATIONAL TRAINING IN AIDS/TB PREVENTION RESEARCH
$229,553Yeshiva University · D43 · FY2002 · TW